IceCure Medical reports Q1 EPS (6c) vs. (8c) last year

Reports Q1 revenue $725K vs. $743K last year. “During Q1, we continued to experience momentum in North America where ProSense sales grew year-over-year. As this market remains a priority for IceCure, we have worked diligently over the past few weeks to prepare the requested Plan, which we delivered to the FDA in a timely manner. Upon the CDRH’s review, we are optimistic about a positive outcome on marketing authorization from the FDA in early-stage low risk breast cancer for women aged 70 and over,” stated CEO Eyal Shamir. “This indication would cover a sizeable population, of approximately 46,000 women in the U.S. annually, that we believe seeks a patient-friendly minimally invasive option. Additionally, we believe that the recent decision by our largest investor and Board member, Mr. Li Haixiang, to provide a $2M unsecured loan demonstrates his confidence in our technology and ability to successfully deliver a less invasive, patient-centered care option–one which we see women in other countries are already benefitting from.”